Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oncaspar

- PMLiVE

SMC approves Yescarta and Keytruda, rejects Perjeta

Cancer drugs lead the latest round of recommendations

AstraZeneca AZ

AstraZeneca sells Losec rights as part of refocus strategy

Funds will be diverted to bolster main therapy areas

- PMLiVE

Lynparza scores another positive phase 3 prostate cancer study

In specific mutations, risk of death was reduced by 66%

- PMLiVE

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

New data in ovarian cancer creates potential for market battle

- PMLiVE

BMS plugs on with Opdivo plus Yervoy in first-line NSCLC

Could be an alternative treatment option to chemotherapy

- PMLiVE

Innate Pharma and AstraZeneca take monalizumab into phase 3

AZ hopes to catch up to rivals using the French biotech's candidate

- PMLiVE

Breath test could predict response to immunotherapy

Study found device accurately predicted responses in lung cancer

AstraZeneca AZ

FDA fast-tracks AstraZeneca’s Farxiga in heart failure

Races to become first-in-class

AstraZeneca AZ

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

New data shows improvement in overall survival

- PMLiVE

Third strike for BMS’ Opdivo in brain cancer

Despite failing first endpoint, trial is set to continue

- PMLiVE

MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups

- PMLiVE

AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes

Reduces CV events but falls down on increased bleeding risk

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links